CardioExchange Archive

September 4th, 2013

Same Disease, Different Tools

Amanda Ruth Vest, MBBS

The standard pharmacological heart-failure treatment may not have changed much in the U.S. recently, but this fellow discovers different approaches in Europe and some potential new drugs on the horizon.

---

September 3rd, 2013

Echo CRT Trial – Going Narrow Doesn’t Broaden CRT Population

Edward J. Schloss, MD

A once promising indication for cardiac resynchronization therapy (CRT) in selected heart failure patients with narrow QRS intervals has suffered a major blow with the premature termination of the Biotronik sponsored multicenter EchoCRT trial.

---

September 3rd, 2013

For CRT, Let ECG — Not Echo — Be Your Guide

Clyde Yancy, MD and John Ryan, MD

Clyde Yancy, coauthor of the NEJM editorial about the EchoCRT Study Group’s randomized trial of echocardiography-guided CRT, provides further insights about the findings.

---

August 19th, 2013

Selections from Richard Lehman’s Literature Review: August 19th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include treating to risk, not to target; perceived job insecurity as a risk factor for incident CHD; ischemic preconditioning in patients undergoing CABG, and more.

---

August 18th, 2013

What Patterns of Change in the Use of Nesiritide Reveal About Hospitals as Learning Organizations

Chohreh Partovian, MD, PhD

Chohreh Partovian discusses her research group’s study of how hospitals varied in their responses to safety concerns about nesiritide from 2005 to 2010.

---

August 5th, 2013

Putting the 2013 Heart Failure Guidelines Into Practice

Clyde Yancy, MD, Harlan M. Krumholz, MD, SM and John Ryan, MD

CardioExchange’s Harlan Krumholz and John Ryan interview Clyde W. Yancy, lead member of the ACCF/AHA task force that wrote the 2013 guidelines for management of heart failure. Krumholz and Ryan: What is the biggest challenge to implementing the heart failure guidelines for every patient with heart failure? Yancy: The biggest challenge is no longer in establishing “proof.” […]

---

July 22nd, 2013

Selections from Richard Lehman’s Literature Review: July 22nd

Richard Lehman, BM, BCh, MRCGP

This week’s topics include combined vasopressin-epinephrine and methylprednisolone after in-hospital cardiac arrest, avoiding NSAIDs for patients with heart failure, and more.

---

July 18th, 2013

BNP-Based Screening + Collaborative Care to Prevent Heart Failure?

John Ryan, MD and Kenneth McDonald, MD

Kenneth McDonald discusses findings from the STOP-HF randomized trial of BNP-based screening versus usual primary care for preventing new-onset heart failure.

---

July 8th, 2013

Selections from Richard Lehman’s Literature Review: July 8th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include a home-based walking intervention for those with PAD, BNP screening and collaborative care for HF, clopidogrel with aspirin in acute minor stroke or transient ischemic attack, and more.

---

June 27th, 2013

Novel Heart Failure Drug from Novartis Gains ‘Breakthrough Therapy’ Designation from FDA

Larry Husten, PHD

Serelaxin, the novel therapy under development for the treatment of acute heart failure, has received a “breakthrough therapy” designation from the FDA, according to Novartis, the company developing the drug. The designation, the FDA explains, “is intended to expedite the development and review of drugs for serious or life-threatening conditions” and requires “preliminary clinical evidence that demonstrates the […]

---